arrow
A

Anna Passarelli

istituto nazionale tumori di napoli irccs g. pascale
H指数:19
被引数:1,308

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network

真实世界分析:接受帕博利珠单抗联合阿昔替尼治疗的转移性肾细胞癌患者——坎帕尼亚肿瘤网络证据

2026-05-310
OA
KELIM score: A marker of chemosensitivity in ovarian cancer

KELIM评分:卵巢癌化疗敏感性的标志物

2025-12-180
PRE
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial

高级别子宫内膜癌中的同源重组修复状态:来自随机、II期MITOEND 3试验的探索性生物标志物分析

2025-12-050
OAAI
The emerging role of PARP inhibitors in prostate cancer: A narrative review

PARP抑制剂在前列腺癌中的新兴作用:一篇叙述性综述

2025-07-250
OAAI
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin plus paclitaxel/avelumab (MITO-END3 trial)

外周单核细胞源性抑制性细胞与单中心接受卡铂联合紫杉醇/阿维单抗治疗子宫内膜癌患者分子亚型的相关性(MITO-END3试验)

2025-04-170
OA
Homologous Recombination Repair Status In Advanced Endometrial Cancer. An Exploratory Biomarker Analysis From The Randomized, Phase II MITO END 3 Trial

高级子宫内膜癌的同源重组修复状态。来自随机、II期MITO END 3试验的探索性生物标志物分析

2025-02-010
PRE
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways
2024-07-012
OAAI
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy
2024-07-014
PRE
Oligometastatic prostate cancer treatment
2021-07-232
PRE